Related Experiment Video
Updated: May 22, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis
Yuki Kagoya1, Yasuhito Nannya, Mineo Kurokawa
1Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Leukemia Research
|May 15, 2012
Summary
Thalidomide maintenance therapy after chemotherapy offers marginal survival benefits for multiple myeloma patients. Combining thalidomide with corticosteroids significantly improves outcomes, but increases risks of thrombosis and neuropathy.
Area of Science:
- Hematology
- Clinical Oncology
- Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy requiring effective maintenance therapies.
- Induction chemotherapy is standard, but post-induction strategies are crucial for long-term control.
- Thalidomide has emerged as a potential agent for maintenance therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of thalidomide maintenance therapy in multiple myeloma.
- To compare thalidomide maintenance with other post-induction regimens.
- To identify patient subgroups benefiting most from thalidomide maintenance.
Main Methods:
- Meta-analysis of randomized controlled trials (RCTs).
- Inclusion of 6 RCTs with 2786 patients.
- Comparison of thalidomide maintenance versus alternative regimens.
Main Results:
- Marginal improvement in overall survival with thalidomide maintenance (HR 0.83, P=0.07).
- Significant survival benefit observed when thalidomide was combined with corticosteroids (HR 0.70, P=0.02).
- Improved progression-free survival (HR 0.65, P<0.01) but increased risks of venous thrombosis and peripheral neuropathy.
Conclusions:
- Thalidomide maintenance, particularly with corticosteroids, demonstrates efficacy in prolonging survival for multiple myeloma.
- Risk-benefit profile requires careful consideration due to increased adverse events like thrombosis and neuropathy.
- Further research may refine optimal use of thalidomide maintenance in multiple myeloma treatment protocols.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...